# Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer

> **NCT01962909** · EARLY_PHASE1 · TERMINATED · sponsor: **University of Virginia** · enrollment: 3 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** PTP-01

## Key facts

- **NCT ID:** NCT01962909
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** From preliminary imaging data, the study was stopped due to futility.
- **Last updated:** 2016-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01962909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01962909, "Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01962909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*